TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05849298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA617
Description: Administration intravenously once every 6 weeks (1 cycle) for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA617
Description: Administration intravenously once every 6 weeks (1 cycle) for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA517
Description: Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAA517
Description: Single intravenous dose of approx. 150 Megabecquerel (MBq) prior PSMA-PET scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piflufolastat F 18
Description: Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piflufolastat F 18
Description: Single intravenous dose of approx. 333 Megabecquerel (MBq) prior PSMA-PET scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARPI
Description: Enzalutamide, Darolutamide, Apalutamide as prescribed by the local investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: as prescribed by the local investigator
Study: NCT04109014

Intervention type: OTHER
Group type: OTHER
Intervention: FASTLANE II
Description: The intervention will consist of nine weekly hour-long individual counseling sessions. The FL II sessions utilize a combination of Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) to reduce sexual risk behaviors and mental health symptoms. Thus, individuals develop a toolbox for mood self-management to improve emotional self-regulation and reduce maladaptive coping mechanisms to minimize drug and sex risk behavior. Participants will be considered as completing the FASTLANE Intervention upon completion of the nine weeks of sessions.
Study: NCT05632835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printing guide plate
Description: 3D-printed customized guide plate will be used to guide the puncture in endoscopic spinal surgeries to help to reduce intra-operative radiation, puncture time, etc..

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional guidance
Description: The surgeons would place the needle according to his/her previous experience under the guidance of C-arm fluoroscopy or CT.
Study: NCT05849298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: as prescribed by the local investigator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: as prescribed by the local investigator
Study: NCT05361655

Intervention type: DRUG
Intervention: Palbociclib + an aromatase inhibitor
Description: Palbociclib + an aromatase inhibitor therapy

Intervention type: DRUG
Intervention: Aromatase inhibitor
Description: Aromatase inhibitor therapy
Study: NCT05684406

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping by Real Time PCR

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping by Real Time PCR
Study: NCT05849298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: as prescribed by the local investigator
Study: NCT06142994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Atusin CAP
Description: This food supplement contains a distillate of 4 types of purified oils - eucalyptus, sweet orange, lemon and myrtle, rich in 1,8-cineol, limonene, alpha-pinene in the ratio: 66:32:1:1, bromelain and green Brazilian propolis in a gastro-resistant capsule. The product contains excipients: microcrystalline cellulose, silica dioxide, copovidone, magnesium stearate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product will be identical in shape, appearance and color to the active product and will have the same composition but without the active ingredients.
Study: NCT06580535

Intervention type: OTHER
Intervention: blood sample
Description: Blood sample taking from patient for tissue culture

Intervention type: OTHER
Intervention: blood sample
Description: Blood sample taking from patient for tissue culture

Intervention type: OTHER
Intervention: blood sample
Description: Blood sample taking from patient for tissue culture
Study: NCT06175026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health messages
Description: Participants view messages about the health impacts of certain dietary substitutions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental messages
Description: Participants view messages about the environmental impacts of certain dietary substitutions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and environmental messages
Description: Participants view messages about the health and environmental impacts of certain dietary substitutions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral messages
Description: Participants view neutral messages unrelated to the health and environmental impacts of certain dietary substitutions.
Study: NCT04974138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: The amlodipine used in this study is a listed product. Amlodipine tablets and amlodipine folic acid (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine 5mg/tablet x5 tablets + amlodipine-folic acid (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine besylate
Description: The amlodipine used in this study is a listed product. Amlodipine tablets and amlodipine folic acid (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine 5mg/tablet x5 tablets + amlodipine-folic acid (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate and folic acid
Description: The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate and folic acid
Description: The amlodipine besylate and folic acid tablets have been approved for listing by the China Food and Drug Administration, approval number: Zhunzi H20180020. Amlodipine-folic acid tablets and amlodipine (dummy) are provided in aluminum-plastic blisters packaging. Each package includes 100 days of treatment drug (including 10 extra days of treatment for the follow-up window). A package of medication consists of 20 plates, each plate includes a total of 10 tablets arranged as follows: amlodipine-folic acid 5.8mg x5 tablets + amlodipine (dummy) x5 tablets. Affixed to the medication package is the randomized treatment drug label (200 tablets/package, 2 tablets/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine placebos
Description: An amlodipine placebo is a dummy pill of an amlodipine tablet with an identical appearance.
Study: NCT06020690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bioabsorbable steroid-releasing stent
Description: The patient after functional endoscopic sinus surgery to treat their chronic sinusitis, the experimental device or active comparator device will be implanted to the sinus to prevent re-intervention (surgery or medicine).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bioabsorbable steroid-releasing stent
Description: The patient after functional endoscopic sinus surgery to treat their chronic sinusitis, the experimental device or active comparator device will be implanted to the sinus to prevent re-intervention (surgery or medicine).
Study: NCT04697264

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood and tissue sample collection from patients with endometrial cancer
Description: Blood and tissue sample collection from patients undergoing surgery for endometrial cancer and blood sample collection only from patients undergoing chemotherapy for endometrial cancer
Study: NCT05182567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-5310 (Group 1)
Description: GLS-5310 DNA plasmid vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-5310 (Group 2)
Description: GLS-5310 DNA plasmid vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-5310 (Group 3)
Description: GLS-5310 DNA plasmid vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-5310 (Group 4)
Description: GLS-5310 DNA plasmid vaccine
Study: NCT05072457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roger On microphone
Description: Roger On microphone transmitter which is used with Roger receivers and Audeo P hearing aids

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roger Select microphone
Description: Roger Select microphone transmitter which is used with Roger receivers and Audeo P hearing aids
Study: NCT04193397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Resistance training program performed during 6 months, 3 sessions per week
Study: NCT06643884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment
Study: NCT04974138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine placebos
Description: An amlodipine placebo is a dummy pill of an amlodipine tablet with an identical appearance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine-folic acid placebos
Description: An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine-folic acid placebos
Description: An Amlodipine folic acid placebo is a dummy pill of an amlodipine folic acid tablet with an identical appearance.
Study: NCT06431841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0,025%
Description: Atropine 0,025% (1 drop per day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine 0,025%
Description: Atropine 0,025% (1 drop per day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIMS Lenses
Description: Use of peripheral defocus lenses with DIMS technology, the design of which simultaneously introduces myopic defocus and provides clear vision to the wearer at all viewing distances.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal lenses
Description: Use of monofocal lenses.
Study: NCT05477901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental cash transfer
Description: Supplemental cash transfer ($40/month)
Study: NCT06270316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-191
Description: A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A.~Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with FD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-191
Description: A recombinant serotype 5 based adeno-associated viral vector (AMT-191) for one-time intravenous (IV) administration will be investigated in this study. This recombinant AAV5-based vector contains a coding deoxyribonucleic acid (DNA) sequence for human α-galactosidase A.~Delivery of AMT-191 to the systemic circulation is expected to result in a therapeutic effect by promoting the liver expression of the lysosomal enzyme GLA in plasma levels in patients with FD.
Study: NCT05545514

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,
Description: To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: One out of 140 predefined homeopathic medical products (HMP) in potency C200 or C1000,
Description: To investigate the efficacy of individualised homeopathic treatment (potency C200 and/or C1000) in comparison to placebo regarding the number of UTI treated with antibiotic agents.
Study: NCT06098729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Exercise
Description: A mobile application that delivers personalized encouragement and data-driven health insights based upon patterns in blood sugar, exercise, mood, and sleep, to assist people with type 1 diabetes in exercising more frequently and confidently
Study: NCT04761198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etigilimab
Description: IV infusion of IV etigilimab every 2 weeks
Study: NCT06643884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS Microinjector
Description: Suprachoroidal Injection Device
Study: NCT05731154

Intervention type: OTHER
Intervention: taking periorbital selfie images using smartphones
Description: taking periorbital selfie images using smartphones
Study: NCT04761198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etigilimab
Description: IV infusion of IV etigilimab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etigilimab
Description: IV infusion of IV etigilimab every 2 weeks
Study: NCT04712435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients will be randomised to receive N-acetylcysteine versus matching placebo
Study: NCT05304637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTEAR100 treatment
Description: Vibratory energy to the external nasal nerve
Study: NCT01304446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren
Description: The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
Study: NCT06341088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral suture sacro-hysteropexy
Description: patients in this group will undergo unilateral sacrouterine ligament plication with nonabsorbable suture and unilaterally suspended to the anterior longitudinal ligament.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral suture sacro-hysteropexy
Description: patients in this group will undergo bilateral sacrouterine ligament plication with nonabsorbable suture and bilaterally suspended to the anterior longitudinal ligament.
Study: NCT04761198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV infusion of nivolumab every 2 weeks
Study: NCT06389760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: When combined with the mFOLFIRINOX regimen, nimotuzumab (nimo) will be administered at a dose of 400mg on Day 1 and 15 of a 28-day cycle (6 cycles). When combined with the GX regimen, nimotuzumab will be given at 400mg on Day 1 and 8 of a 21-day cycle (8 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Patients will receive mFOLFIRINOX as follows: Oxaliplatin 65 mg/m2 on Day 1 and 15 of a 28-day cycle; Irinotecan 130 mg/m2 on Day 1 and 15 of a 28-day cycle; Leucovorin(LV) 200 mg/m2 Day 1 and 15 of a 28-day cycle; 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day 1 and 15 of a 28-day cycle (6 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX
Description: Patients will receive GX regimen as follows: Gemcitabine 1000 mg/m2 on Day 1 and 8 of a 21-day cycle; capecitabine 2000 mg/m2 on d1-14 a 21-day cycle(8 cycles).
Study: NCT05562479

Intervention type: BIOLOGICAL
Intervention: Sars Cov 2 infection
Description: Donors recovered from Sars Cov 2 Infection

Intervention type: BIOLOGICAL
Intervention: Sars Cov 2 vaccination
Description: Egg Donors vaccinated
Study: NCT04805060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 administered intravenously (IV) on Day 1 of each 21-day. The established dose of TQB2858 is diluted with normal saline \[0.9% (w/v) sodium chloride solution\], and the infusion time is 60 ± 10 min.
Study: NCT04560166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naxitamab and GM-CSF in combination with irinotecan and temozolomide
Description: * Irinotecan, solution for infusion (20 mg/mL)~* Temozolomide, capsules (5 mg, 20 mg and 100 mg)~* The humanized immunoglobulin isotype G (IgG1) monoclonal antibody (mAb) naxitamab, solution for infusion (4 mg/mL)~* Sargramostim (GM-CSF), lyophilized 250 µg single use vial (250 µg/vial)
Study: NCT04649502

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin in combination with doxycycline

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin in combination with doxycycline
Study: NCT05650164

Intervention type: DRUG
Intervention: avelumab
Description: as provided in real world practice

Intervention type: DRUG
Intervention: axitinib
Description: as provided in real world practice
Study: NCT06200844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC 5D
Description: Rotavirus Vaccine (ROTAVAC 5D), is a monovalent vaccine containing suspension of live attenuated rotavirus 116E prepared in Vero cells, containing NLT 105.0 FFU and administered as a three-dose regimen, 4 weeks apart.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as three doses 4 weeks apart
Study: NCT05065489

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06369779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TM Fill in combination with TM Flow
Description: The newly developed resin composites (TM Flow in combination with TM Fill) will be used for the restoration of class I and II cavities (3 seconds light-curing mode, 3000 milliwatt per square centimeter).
Study: NCT06643884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS Microinjector
Description: Suprachoroidal Injection Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Laser Administration
Study: NCT05797961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV self-testing with online supervision
Description: A pilot study to assess the feasibility of HIV self-testing with online supervision

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: venue-based HIV testing
Study: NCT05206253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole egg powder
Description: Nutritional supplementation during a 12 week resistance training program

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein powder
Description: Nutritional supplementation during a 12 week resistance training program

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin placebo
Description: Nutritional supplementation during a 12 week resistance training program
Study: NCT05500339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M-health App
Description: Pregnant women receive the App designed for the support of the first 1000 days of life

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard care
Description: Pregnant women receive standard supportive and educational methods.
Study: NCT05307380

Intervention type: DIAGNOSTIC_TEST
Intervention: functional pain scale
Description: French translation of the Defence and Veterans Pain Rating Scale (DVPRS)